3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
10
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
140
Breast
12
Gynecologic
4
Gastrointestinal
4
Tumor-Agnostic
2
Lymphoid
2
Thoracic
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Dermatologic
1
Classical hematology
1
Conditions
Neoplasms
1
Neoplasm Metastasis
1
Interventions
Surveys and Questionnaires
70
Blood Specimen Collection
48
Radiotherapy
39
Magnetic Resonance Spectroscopy
35
pembrolizumab
31
Gemcitabine
30
Bevacizumab
30
Nivolumab
29
Carboplatin
29
Radiosurgery
27
Standard of Care
26
Oxaliplatin
26
Capecitabine
25
Paclitaxel
24
Interviews as Topic
24
Cisplatin
24
Fluorouracil
23
Erlotinib Hydrochloride
22
Everolimus
19
Irinotecan
18
Trastuzumab
17
Methods
17
Exercise
17
Docetaxel
17
Biopsy
17
Cyclophosphamide
16
Educational Status
15
Sorafenib
14
Ipilimumab
14
Fluorodeoxyglucose F18
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
enzalutamide
×
Tumor-Agnostic
×
Clear all
NCT03314324
2025-04-17
ODENZA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
250 enrolled
NCT03295565
2022-04-15
OSTRICh
The Netherlands Cancer Institute
Phase 2/3
Completed
100 enrolled